KCM Investment Advisors’s AbbVie ABBV Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$16.7M Buy
76,791
+559
+0.7% +$124K 0.55% 45
2025
Q4
$17.4M Sell
76,232
-108
-0.1% -$24.6K 0.56% 46
2025
Q3
$17.7M Sell
76,340
-87
-0.1% -$17.7K 0.57% 45
2025
Q2
$14.2M Buy
76,427
+746
+1% +$139K 0.48% 46
2025
Q1
$15.9M Sell
75,681
-2,392
-3% -$465K 0.57% 44
2024
Q4
$13.9M Sell
78,073
-719
-0.9% -$132K 0.48% 47
2024
Q3
$15.6M Buy
78,792
+981
+1% +$183K 0.53% 47
2024
Q2
$13.3M Sell
77,811
-1,729
-2% -$286K 0.48% 48
2024
Q1
$14.5M Buy
79,540
+108
+0.1% +$18.6K 0.54% 48
2023
Q4
$12.3M Sell
79,432
-2,941
-4% -$429K 0.49% 53
2023
Q3
$12.3M Sell
82,373
-3,196
-4% -$469K 0.53% 51
2023
Q2
$11.5M Sell
85,569
-2,705
-3% -$397K 0.46% 55
2023
Q1
$14.1M Buy
88,274
+1,231
+1% +$188K 0.57% 52
2022
Q4
$14.1M Buy
87,043
+191
+0.2% +$29.3K 0.61% 51
2022
Q3
$11.7M Buy
86,852
+1,789
+2% +$257K 0.54% 52
2022
Q2
$13M Buy
85,063
+1,281
+2% +$196K 0.57% 52
2022
Q1
$13.6M Buy
83,782
+2,440
+3% +$354K 0.5% 56
2021
Q4
$11M Buy
81,342
+6,530
+9% +$771K 0.38% 64
2021
Q3
$8.07M Buy
74,812
+1,930
+3% +$221K 0.32% 71
2021
Q2
$8.21M Buy
72,882
+5,899
+9% +$664K 0.33% 71
2021
Q1
$7.25M Buy
66,983
+13,613
+26% +$1.46M 0.32% 74
2020
Q4
$5.72M Buy
53,370
+21,252
+66% +$2.04M 0.28% 81
2020
Q3
$2.81M Buy
32,118
+289
+0.9% +$27.2K 0.16% 108
2020
Q2
$3.13M Buy
31,829
+912
+3% +$80.3K 0.18% 108
2020
Q1
$2.36M Sell
30,917
-1,061
-3% -$90.4K 0.16% 105
2019
Q4
$2.83M Sell
31,978
-1,249
-4% -$104K 0.15% 114
2019
Q3
$2.52M Sell
33,227
-26,081
-44% -$1.79M 0.15% 117
2019
Q2
$4.31M Buy
59,308
+265
+0.4% +$20.8K 0.26% 91
2019
Q1
$4.76M Sell
59,043
-68,858
-54% -$5.63M 0.31% 84
2018
Q4
$11.8M Sell
127,901
-10,251
-7% -$901K 0.78% 38
2018
Q3
$13.1M Sell
138,152
-7,670
-5% -$727K 0.75% 36
2018
Q2
$13.5M Sell
145,822
-2,953
-2% -$288K 0.83% 32
2018
Q1
$14.1M Sell
148,775
-3,657
-2% -$402K 0.86% 31
2017
Q4
$14.7M Sell
152,432
-2,331
-2% -$220K 0.86% 30
2017
Q3
$13.8M Sell
154,763
-2,075
-1% -$158K 0.84% 28
2017
Q2
$11.4M Sell
156,838
-3,023
-2% -$203K 0.71% 35
2017
Q1
$10.4M Sell
159,861
-1,102
-0.7% -$69.3K 0.67% 37
2016
Q4
$10.1M Buy
160,963
+1,487
+0.9% +$90.8K 0.68% 35
2016
Q3
$10.1M Buy
159,476
+2,406
+2% +$156K 0.69% 35
2016
Q2
$9.72M Sell
157,070
-1,562
-1% -$95.2K 0.68% 36
2016
Q1
$9.06M Buy
158,632
+10,710
+7% +$597K 0.67% 41
2015
Q4
$8.76M Sell
147,922
-1,336
-0.9% -$77K 0.69% 37
2015
Q3
$8.12M Buy
149,258
+6,153
+4% +$401K 0.67% 38
2015
Q2
$9.62M Sell
143,105
-3,861
-3% -$252K 0.76% 26
2015
Q1
$8.6M Buy
146,966
+3,724
+3% +$225K 0.69% 33
2014
Q4
$9.37M Buy
143,242
+3,111
+2% +$196K 0.79% 27
2014
Q3
$8.09M Sell
140,131
-33
-0% -$1.83K 0.74% 27
2014
Q2
$7.91M Buy
140,164
+9,020
+7% +$473K 0.74% 27
2014
Q1
$6.74M Buy
131,144
+13,248
+11% +$670K 0.7% 29
2013
Q4
$6.23M Sell
117,896
-1,308
-1% -$64.3K 0.68% 30
2013
Q3
$5.33M Sell
119,204
-33,149
-22% -$1.47M 0.64% 34
2013
Q2
$6.3M Buy
+152,353
New +$6.66M 0.76% 28

Other funds holding ABBV

KCM Investment Advisors's ABBV Position: Q1 2026 in Review

KCM Investment Advisors increased its AbbVie (ABBV) stake by 0.73% in Q1 2026, buying an estimated $124K and bringing the position to 76,791 shares worth $16.7M. The position accounts for 0.55% of the portfolio, ranked #45.

KCM Investment Advisors first reported a position in ABBV in Q2 2013 and has held it in 52 quarters since. The position peaked at $17.7M in Q3 2025. 4,077 funds tracked by Wall St. Rank hold ABBV as of Q1 2026.

  • KCM Investment Advisors held 76,791 shares of AbbVie worth $16.7M as of Q1 2026.
  • KCM Investment Advisors bought 559 AbbVie shares in Q1 2026, an estimated $124K.
  • AbbVie made up 0.55% of KCM Investment Advisors's portfolio in Q1 2026, its #45 holding.
  • KCM Investment Advisors first reported a position in AbbVie in Q2 2013 and has held it in 52 quarters since.
  • KCM Investment Advisors's AbbVie position peaked at $17.7M in Q3 2025.
  • 4,077 funds tracked by Wall St. Rank held AbbVie as of Q1 2026.

Based on KCM Investment Advisors's 13F filing for Q1 2026, filed 15 May 2026.